S. V. Van Wart

发表

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.

B. Cirincione, S. Bhavnani, P. Ambrose, 2009, Diagnostic microbiology and infectious disease.

Pharmacokinetics and Leukocyte Responses of Recombinant Human Interleukin-10

W. Jusko, E. Radwanski, D. Cutler, 1998, Pharmaceutical Research.

Population‐based meta‐analysis of hydrochlorothiazide pharmacokinetics

S. Shoaf, D. Mager, S. V. Van Wart, 2013, Biopharmaceutics & drug disposition.

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

S. Bhavnani, P. Ambrose, A. Forrest, 2009, Antimicrobial Agents and Chemotherapy.

Randomized Pharmacokinetic and Pharmacodynamic Comparison of Fluoroquinolones for Tuberculous Meningitis

J. Farrar, T. Hien, G. Thwaites, 2011, Antimicrobial Agents and Chemotherapy.

A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function

S. V. Van Wart, Allison S. Komirenko, J. Seroogy, 2018, Antimicrobial Agents and Chemotherapy.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

B. Cirincione, J. Korth-Bradley, P. Ambrose, 2009, Diagnostic microbiology and infectious disease.

Population pharmacokinetic analysis of clopidogrel in healthy Jordanian subjects with emphasis optimal sampling strategy

T. Arafat, S. V. Van Wart, M. Melhem, 2013, Biopharmaceutics & drug disposition.

Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure Infections

E. Ludwig, B. Cirincione, J. Korth-Bradley, 2006, Antimicrobial Agents and Chemotherapy.

Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor

J. Sloan-Lancaster, S. V. Van Wart, C. Rubino, 2013, CPT: pharmacometrics & systems pharmacology.

Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis

S. Shoaf, D. Mager, S. V. Van Wart, 2013, Biopharmaceutics & drug disposition.

Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue

J. Baldassarre, M. Dunne, S. V. Van Wart, 2015, Antimicrobial Agents and Chemotherapy.

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival

M. Neely, D. Nicolau, Jiajun Liu, 2015, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

S. Bhavnani, P. Ambrose, L. Friedrich, 2020, Antimicrobial Agents and Chemotherapy.

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.

Ronald N. Jones, M. Piedmonte, J. Anon, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study

W. Gahl, J. Heiss, M. Huizing, 2021, Genetics in Medicine.

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

D. Andes, Varsha Iyer, S. Bhavnani, 2011, Antimicrobial Agents and Chemotherapy.

Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization

D. Andes, S. Bhavnani, A. Lepak, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)

Akram Khan, R. Wunderink, Yasir Hamad, 2020, Antimicrobial Agents and Chemotherapy.

A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics

S. V. Van Wart, T. Choi, Jonathan Gall, 2019, Clinical pharmacology in drug development.

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies

S. Bhavnani, P. Ambrose, Aryun Kim, 2019, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies

C. Rayner, S. Toovey, S. Bhavnani, 2013, Antimicrobial Agents and Chemotherapy.

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections

B. Cirincione, P. Ambrose, J. Passarell, 2007, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy

M. Huizing, D. Mager, S. V. Van Wart, 2021, Drugs in R&D.

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections

B. Cirincione, P. Ambrose, J. Passarell, 2007, Antimicrobial Agents and Chemotherapy.

Population‐based meta‐analysis of furosemide pharmacokinetics

Donald E Mager, S. Shoaf, D. Mager, 2014, Biopharmaceutics & drug disposition.

Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia

T. Riccobene, S. Bhavnani, P. Ambrose, 2013, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections

E. Ludwig, D. Gajjar, D. Grasela, 2004, Antimicrobial Agents and Chemotherapy.

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes

Lawrence Corey, Joshua T. Schiffer, Amalia Magaret, 2016, Science Translational Medicine.

1089. Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)

L. Walker, P. Ambrose, L. Connolly, 2021, Open Forum Infectious Diseases.

1088. A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)

L. Walker, D. Mager, D. Shah, 2021, Open Forum Infectious Diseases.

Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a 'Goldilocks' window.

D. Nicolau, M. Scheetz, Cristina M Miglis, 2017, International journal of antimicrobial agents.

Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.

D. Andes, S. Bhavnani, P. Ambrose, 2009, Diagnostic microbiology and infectious disease.

Population‐based meta‐analysis of hydrochlorothiazide pharmacokinetics

S. Shoaf, D. Mager, S. V. Van Wart, 2013, Biopharmaceutics & drug disposition.

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.

Ronald N. Jones, M. Piedmonte, J. Anon, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetic-Pharmacodynamic Analysis for Efficacy of Ceftaroline Fosamil in Patients with Acute Bacterial Skin and Skin Structure Infections

G. Drusano, T. Riccobene, S. Bhavnani, 2014, Antimicrobial Agents and Chemotherapy.